多嚢胞性卵巣症候群(PCOS)治療薬の世界市場2021年-2025年

◆英語タイトル:Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2021-2025
◆商品コード:IRTNTR70204
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年2月15日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他の地域
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥287,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥345,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥460,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社の本調査レポートでは、世界の多嚢胞性卵巣症候群(PCOS)治療薬市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、薬物クラス別(インスリン増感剤、経口避妊薬、アロマターゼ阻害剤、その他)分析、顧客状況、地域別状況、企業状況、企業分析などの項目を掲載しています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の多嚢胞性卵巣症候群(PCOS)治療薬市場規模:薬物クラス別(インスリン増感剤、経口避妊薬、アロマターゼ阻害剤、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2021-2025
Technavio has been monitoring the polycystic ovary syndrome (PCOS) drugs market and it is poised to grow by $ 711.14 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on polycystic ovary syndrome (PCOS) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases and growth in the geriatric women population. In addition, increasing prevalence of chronic diseases is anticipated to boost the growth of the market as well.
The polycystic ovary syndrome (PCOS) drugs market analysis includes application segment and geographical landscapes.
Technavio’s polycystic ovary syndrome (PCOS) drugs market is segmented as below:

By Application
• Insulin sensitizing agents
• Oral contraceptives
• Aromatase inhibitors
• Other drug classes

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies increasing rate of unplanned pregnancies and unnecessary abortions as one of the prime reasons driving the polycystic ovary syndrome (PCOS) drugs market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on polycystic ovary syndrome (PCOS) drugs market covers the following areas:
• Polycystic ovary syndrome (PCOS) drugs market sizing
• Polycystic ovary syndrome (PCOS) drugs market forecast
• Polycystic ovary syndrome (PCOS) drugs market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic ovary syndrome (PCOS) drugs market vendors that include AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the polycystic ovary syndrome (PCOS) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – [https://www.technavio.com/report/report/polycystic-ovary-syndrome-(PCOS)-drugs-market-industry-analysis](https://www.technavio.com/report/polycystic-ovary-syndrome-(pcos)-drugs-market-industry-analysis)

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Drug Class
o Market segments
o Comparison by drug class
o Insulin sensitizing agents – Market size and forecast 2020-2025
o Oral contraceptives – Market size and forecast 2020-2025
o Aromatase inhibitors – Market size and forecast 2020-2025
o Other drug classes – Market size and forecast 2020-2025
o Market opportunity by drug class
• Customer landscape
o Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive scenario
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AbbVie Inc.
o Bayer AG
o Bristol-Myers Squibb Co.
o Cipla Inc.
o Ferring Pharmaceuticals AS
o Merck & Co. Inc.
o Novartis AG
o Pfizer Inc.
o Sun Pharmaceutical Industries Ltd.
o Teva Pharmaceutical Industries Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Other1 – Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Insulin sensitizing agents – Market size and forecast 2020-2025 ($ million)
• 24: Insulin sensitizing agents – Year-over-year growth 2020-2025 (%)
• 25: Oral contraceptives – Market size and forecast 2020-2025 ($ million)
• 26: Oral contraceptives – Year-over-year growth 2020-2025 (%)
• 27: Aromatase inhibitors – Market size and forecast 2020-2025 ($ million)
• 28: Aromatase inhibitors – Year-over-year growth 2020-2025 (%)
• 29: Other drug classes – Market size and forecast 2020-2025 ($ million)
• 30: Other drug classes – Year-over-year growth 2020-2025 (%)
• 31: Market opportunity by Other1
• 32: Customer landscape
• 33: Market share by geography 2020-2025 (%)
• 34: Geographic comparison
• 35: North America – Market size and forecast 2020-2025 ($ million)
• 36: North America – Year-over-year growth 2020-2025 (%)
• 37: Europe – Market size and forecast 2020-2025 ($ million)
• 38: Europe – Year-over-year growth 2020-2025 (%)
• 39: Asia – Market size and forecast 2020-2025 ($ million)
• 40: Asia – Year-over-year growth 2020-2025 (%)
• 41: ROW – Market size and forecast 2020-2025 ($ million)
• 42: ROW – Year-over-year growth 2020-2025 (%)
• 43: Key leading countries
• 44: Market opportunity by geography ($ million)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: AbbVie Inc. – Overview
• 52: AbbVie Inc. – Business segments
• 53: AbbVie Inc. – Key offerings
• 54: AbbVie Inc. – Key customers
• 55: AbbVie Inc. – Segment focus
• 56: Bayer AG – Overview
• 57: Bayer AG – Business segments
• 58: Bayer AG – Key offerings
• 59: Bayer AG – Key customers
• 60: Bayer AG – Segment focus
• 61: Bristol-Myers Squibb Co. – Overview
• 62: Bristol-Myers Squibb Co. – Product and service
• 63: Bristol-Myers Squibb Co. – Key offerings
• 64: Bristol-Myers Squibb Co. – Key customers
• 65: Bristol-Myers Squibb Co. – Segment focus
• 66: Cipla Inc. – Overview
• 67: Cipla Inc. – Business segments
• 68: Cipla Inc. – Key offerings
• 69: Cipla Inc. – Key customers
• 70: Cipla Inc. – Segment focus
• 71: Ferring Pharmaceuticals AS – Overview
• 72: Ferring Pharmaceuticals AS – Product and service
• 73: Ferring Pharmaceuticals AS – Key offerings
• 74: Ferring Pharmaceuticals AS – Key customers
• 75: Ferring Pharmaceuticals AS – Segment focus
• 76: Merck & Co. Inc. – Overview
• 77: Merck & Co. Inc. – Business segments
• 78: Merck & Co. Inc. – Key offerings
• 79: Merck & Co. Inc. – Key customers
• 80: Merck & Co. Inc. – Segment focus
• 81: Novartis AG – Overview
• 82: Novartis AG – Business segments
• 83: Novartis AG – Key offerings
• 84: Novartis AG – Key customers
• 85: Novartis AG – Segment focus
• 86: Pfizer Inc. – Overview
• 87: Pfizer Inc. – Business segments
• 88: Pfizer Inc. – Key offerings
• 89: Pfizer Inc. – Key customers
• 90: Pfizer Inc. – Segment focus
• 91: Sun Pharmaceutical Industries Ltd. – Overview
• 92: Sun Pharmaceutical Industries Ltd. – Business segments
• 93: Sun Pharmaceutical Industries Ltd. – Key offerings
• 94: Sun Pharmaceutical Industries Ltd. – Key customers
• 95: Sun Pharmaceutical Industries Ltd. – Segment focus
• 96: Teva Pharmaceutical Industries Ltd. – Overview
• 97: Teva Pharmaceutical Industries Ltd. – Business segments
• 98: Teva Pharmaceutical Industries Ltd. – Key offerings
• 99: Teva Pharmaceutical Industries Ltd. – Key customers
• 100: Teva Pharmaceutical Industries Ltd. – Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations



【掲載企業】

AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[多嚢胞性卵巣症候群(PCOS)治療薬の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆